Company Overview - Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing innovative tissue repair solutions aimed at restoring health and enhancing the quality of life for patients [5] - The company's primary focus is on orthopedic treatments utilizing its Gelrin platform, which is based on degradable hydrogel implants to regenerate damaged or diseased tissue [5] Initial Public Offering (IPO) Details - The company announced the closing of its IPO, offering 1,250,000 ordinary shares at a public offering price of $8.00 per share, resulting in aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses [1][2] - The ordinary shares began trading on the NYSE American LLC under the symbol "RGNT" on December 4, 2025 [2] - The company granted underwriters a 45-day option to purchase up to an additional 187,500 ordinary shares to cover over-allotments [1] Use of Proceeds - The net proceeds from the offering will primarily be used for development activities, including the completion of a pivotal trial and preparation for the PMA submission for GelrinC, as well as for corporate purposes such as repaying certain debt and deferred compensation payments [2] Product Information - GelrinC is the company's lead product candidate, designed as a cell-free, off-the-shelf hydrogel that serves as a temporary implant for treating painful injuries to articular knee cartilage [5] - GelrinC has received a Conformité Européene (CE) mark in Europe, allowing the company to initiate commercialization efforts in that region while also focusing on obtaining FDA approval in the United States [5]
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering